Helicobacter Pylori Non-Invasive Testing Market

Helicobacter pylori (H. pylori) is a Gram-negative, microaerobic human pathogen and H. pylori infection is strongly related with many gastroduodenal diseases including chronic active gastritis, peptic ulcer diseases, atrophic gastritis, mucosa associated lymphoid tissue (MALT) lymphoma and noncardia gastric cancer. H. pylori infection affects more than half of the adult population worldwide, but the prevalence of H pylori infection varies widely by geographic area, age, race, and socioeconomic status. Usually, the prevalence of H. pylori increases with age in most countries, however a decline in prevalence of H. pylori infection has been observed in recent decades in time trend analysis of several large populations. More than 80% of peptic ulcer diseases are caused by H. pylori infection and the estimated lifetime risk for peptic ulcer disease in H. pylori-infected patients is approximately 15%. Gastric cancer is the third leading cause of cancer-related death worldwide and H. pylori infection is responsible for 74.7% of all noncardia gastric cancer cases. Gastric cancer and peptic ulcer together cause more than a million deaths per year in the world and H. pylori infection always is an important health issue. Various diagnostic methods are developed to detect H. pylori infection and diagnostic tests with both high sensitivity and specificity, exceeding 90%, are necessary for accurate diagnosis of H. pylori infection in clinical practice. Although many diagnostic tests are available now, each method has its own advantages, disadvantages, and limitations. The choice of one method or another could be depended on availability and accessibility of diagnostic tests, level of laboratories, clinical conditions of patients, and likelihood ratio of positive and negative tests on different clinical circumstances.

Diagnostic tests are usually divided into invasive (endoscopic-based) and noninvasive methods. Helicobacter Pylori Non-Invasive Testing Market studies the Helicobacter Pylori (H-Pylori) Non-Invasive Testing market, Non-invasive diagnostic tests included stool antigen test, serological, and urea breath test, etc.

Helicobacter Pylori Non-Invasive Testing Market contains market size and forecasts of Helicobacter Pylori (H-Pylori) Non-Invasive Testing in global, including the following market information:

• Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Helicobacter Pylori (H-Pylori) Non-Invasive Testing companies in 2021 (%)

The global Helicobacter Pylori (H-Pylori) Non-Invasive Testing market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Urea Breath Test Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Helicobacter Pylori (H-Pylori) Non-Invasive Testing include Sekisui Diagnostics, Roche, Danaher, Abbott Laboratories, Medline Industries, Bio-Rad Laboratories, Thermo Fisher Scientific, Quidel and Cardinal Health, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Helicobacter Pylori (H-Pylori) Non-Invasive Testing manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Segment Percentages, by Type, 2021 (%)

• Urea Breath Test
• Serology Test
• Stool Antigen Test
• Others

Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Physical Examination Center
• Others

Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Helicobacter Pylori (H-Pylori) Non-Invasive Testing Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Helicobacter Pylori (H-Pylori) Non-Invasive Testing revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Helicobacter Pylori (H-Pylori) Non-Invasive Testing revenues share in global market, 2021 (%)
• Key companies Helicobacter Pylori (H-Pylori) Non-Invasive Testing sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Helicobacter Pylori (H-Pylori) Non-Invasive Testing sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sekisui Diagnostics
• Roche
• Danaher
• Abbott Laboratories
• Medline Industries
• Bio-Rad Laboratories
• Thermo Fisher Scientific
• Quidel
• Cardinal Health
• Agilent Technologies
• Meridian Bioscience
• Biomerica
• DiaSorin S.p.A
• Alpha Laboratories
• EKF Diagnostics
• Halyard Health, Inc
• Coris BioConcept
• Certest Biotec SL
• Otsuka Pharmaceutical
• Savyon Diagnostics
• Kibion AB
• Boditech Med Inc
• Shenzhen Zhonghe Headway Bio-Sci & Tech